LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approved
LIVZON PHARMA (01513.HK) announced that the JP-1366 tablets it applied for have been approved by the National Medical Products Administration to conduct clinical trials for the indication "to eradicate Helicobacter pylori in combination with appropriate antibiotics."
JP-1366 tablets are an innovative potassium ion competitive acid blocker. Previously, its application for marketing for the treatment of gastroesophageal reflux disease was accepted in August 2025; while the injectable form for the treatment of bleeding peptic ulcers has entered Phase II clinical trials in October 2025
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments